2025-523474-16-00招募中2 期
A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 105
- 试验地点
- 17
- 主要终点
- Dose Escalation: Incidence of dose-limiting toxicities occurring within the first 28-day cycle Number of Adverse Events and Serious Adverse Events Dose Expansion: Objective response
研究概览
简要总结
Dose Escalation: To evaluate the safety and tolerability of S241656 in the different indications and cumulatively when administered as monotherapy and in combination Dose Expansion: To evaluate the antitumor activity of S241656 when administered as a monotherapy and in combination
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Life expectancy of ≥ 12 weeks in the opinion of the investigator
- •Histologically or cytologically confirmed recurrent locally advanced (unresectable) or metastatic solid tumors with documented RAS or RAF mutations or alterations.
- •Adequate bone marrow and organ function.
- •Recovered from toxicity to prior anti-cancer therapy.
- •Part 1 Dose Escalation cohort ONLY: • Part 1A: Advanced/metastatic NSCLC with KRAS non-G12C, HRAS, NRAS, BRAF or CRAF (RAF1) mutations or alterations • Part 1B: Advanced/metastatic GI tumors (e.g., PDAC, CRC, and BTC) with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations • Part 1C: Advanced/metastatic PDAC with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations • Part 1D: Colorectal adenocarcinoma with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations • Part 1E: Other advanced/metastatic non-GI, non-NSCLC solid tumors with KRAS, HRAS, NRAS, BRAF, CRAF (RAF1) mutations or alterations
- •Part 2 Dose Optimization and Expansion cohorts ONLY: • Part 2A: Advanced/metastatic NSCLC with KRAS non-G12C mutations and/or BRAF mutations • Part 2A1: Advanced/metastatic NSCLC with KRAS non-G12C mutations • Part 2A2: Advanced/metastatic NSCLC with BRAF mutations • Part 2A3: Advanced/metastatic NSCLC with KRAS non-G12C or BRAF mutations or alterations and active CNS metastatic disease • Part 2A4: Advanced/metastatic NSCLC with a KRAS G12C mutation • Part 2B1: Advanced/metastatic PDAC with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations • Part 2B2: Advanced/metastatic CRC with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations • Part 2B3: Advanced/metastatic BTC (adenocarcinoma) with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations
排除标准
- •Cancer that has a known MEK1/2 mutation.
- •Ongoing anticancer therapy.
- •Ongoing radiation therapy.
- •Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy.
- •Clinically significant cardiovascular disease.
- •Symptomatic spinal cord compression.
- •History or current evidence of non-infectious interstitial lung disease (ILD), pneumonitis, or pulmonary fibrosis
- •Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years.
- •History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.
- •Females who are pregnant or breastfeeding.
- •Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.
- •Prior use of experimental agents that target the KRAS/BRAF/MEK/ERK pathway.
- •Known allergy/hypersensitivity to excipients of S241656 or to any of the registered IMPs administered in combination.
- •Any contra-indication, to use of any of the combination chemotherapy or anti-EGFR therapy partners administered as part of this trial.
- •Major surgery within 4 weeks of study entry or planned during study.
研究组 & 干预措施
Vectibix 20 mg/ml concentrate for solution for infusion
Test
干预措施: Vectibix 20 mg/ml concentrate for solution for infusion (Drug)
Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Test
干预措施: Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung (Drug)
FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion
Test
干预措施: FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion (Drug)
Bugvi 5 mg/ml pulbere pentru dispersie perfuzabilă
Test
干预措施: Bugvi 5 mg/ml pulbere pentru dispersie perfuzabilă (Drug)
Erbitux 5 mg/mL solution for infusion
Test
干预措施: Erbitux 5 mg/mL solution for infusion (Drug)
Fluorouracil Hikma 50 mg/ml Injektionslösung
Test
干预措施: Fluorouracil Hikma 50 mg/ml Injektionslösung (Drug)
Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Test
干预措施: Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung (Drug)
Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Test
干预措施: Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung (Drug)
结局指标
主要结局
Dose Escalation: Incidence of dose-limiting toxicities occurring within the first 28-day cycle Number of Adverse Events and Serious Adverse Events Dose Expansion: Objective response
Dose Escalation: Incidence of dose-limiting toxicities occurring within the first 28-day cycle Number of Adverse Events and Serious Adverse Events Dose Expansion: Objective response
次要结局
- 1. Dose Escalation: PK parameters of S241656 and its metabolite S243796, including but not limited to Cmax, tmax, AUC, and t½
- 2. Dose Escalation: Objective response Disease Control Clinical Benefit Duration of Response Time to response Progression free survival Overall survival
- 3. Dose Escalation: Clinical efficacy parameters Safety and tolerability parameters PK including: Exposure-toxicity relationship
- 4. Dose Expansion: Clinical Efficacy Parameters Safety and Tolerability Parameters PK & PD parameters
- 5. Dose Expansion: Disease Control Clinical Benefit Duration of Response Time to Response Progression free survival Overall Survival
- 6. Dose Expansion: PK parameters of S241656 and its metabolite S243796, but not limited to Cmax, tmax, AUC, and t½
研究者
Clinical Studies Department
Scientific
Institut De Recherches Internationales Servier IRIS
研究点 (17)
Loading locations...
相似试验
招募中
1 期
Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSCNCT07355972Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12
已完成
2 期
Safety and preliminary efficacy trial of BNT142 in patients with CLDN6-positive advanced ovarian, lung, or testicular cancer2024-512639-58-00BioNTech SE119
招募中
1 期
BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid TumorsNCT07469774Biocity Biopharmaceutics Co., Ltd.111
招募中
1 期
QLS5212 for Participants With Advanced Solid TumorsNCT07467629Qilu Pharmaceutical Co., Ltd.100
招募中
2 期
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies2023-509847-29-00BioInvent International AB231